Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD: Eribulin vs Taxane with HP in HER2+ Breast Cancer
NCT03264547Phase 3Completed
- Sponsor
- Japan Breast Cancer Research Group
- Start
- Aug 2017
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eribulin in HER2-positive breast cancer, sponsored by Japan Breast Cancer Research Group. Started Aug 2017; status: completed.
02
Drugs
eribulin
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03264547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03264547.